Doug Bickerstaff Diagnosed With Stage IV Lung Cancer After Arm Fracture

Doug Bickerstaff, a paramedic from Cabarrus County, was diagnosed with stage IV non-small cell lung cancer (NSCLC) in February 2026 after a spontaneous arm fracture during a training class.

His case highlights the critical shift toward targeted therapies for patients harboring specific genetic mutations, even those with no smoking history.

Clinical Insights for Patients

• Genetic Testing: Patients with non-small cell lung cancer should receive comprehensive biomarker testing to identify specific mutations like ALK fusions.
• Targeted Therapy vs. Chemotherapy: Unlike traditional chemotherapy, which attacks all rapidly dividing cells, targeted therapy interferes with specific proteins that drive tumor growth, often resulting in fewer systemic side effects.
• Advanced Presentation: Lung cancer can present through skeletal symptoms, such as pathological fractures, emphasizing the need for oncological screening when unexplained bone pain occurs.

The Path from Emergency Responder to Patient

For three decades, Doug Bickerstaff served as a paramedic in Cabarrus County, responding to the medical crises of others. In February 2026, the roles reversed when he experienced a sudden, sharp pain in his left arm while teaching an EMS continuing education class at the Rowan County EMS Station. The pain was the result of a pathological fracture—a break caused by a lesion weakening the bone structure.

Imaging conducted at Atrium Health Cabarrus revealed a suspicious mass, leading to surgical stabilization with a metal rod. Subsequent biopsy analysis by the oncology team at Atrium Health Levine Cancer confirmed a diagnosis of stage IV non-small cell lung cancer that had metastasized to the skeletal system. As reported by Atrium Health, the diagnosis was unexpected, as Bickerstaff has no history of tobacco use.

ALK Fusion Mutations Drive Precise Cancer Treatment

Following the discovery of metastatic lesions in his femur and upper arm, Bickerstaff’s clinical team identified a rare genetic alteration known as an ALK (anaplastic lymphoma kinase) fusion. This specific mutation occurs in approximately 3% to 5% of NSCLC cases. According to Dr. Daniel Haggstrom, an oncologist at Levine Cancer, this finding allowed for a shift away from conventional cytotoxic chemotherapy toward a more precise treatment modality.

Targeted therapies for ALK-positive cancers function by inhibiting the aberrant signaling proteins that instruct cancer cells to proliferate. By blocking these pathways, the medication can induce tumor regression while sparing healthy tissue. The clinical trial Bickerstaff joined at Levine Cancer is part of a broader effort to refine these therapies, which aim to improve survival outcomes in advanced-stage patients while maintaining a higher quality of life.

Treatment Type	Mechanism of Action	Primary Benefit
Traditional Chemotherapy	Broad DNA/Cell division inhibition	Systemic tumor reduction
Targeted Therapy (ALK)	Specific protein signaling inhibition	Precision targeting; reduced toxicity

Molecular Profiling Determines If Targeted Therapies Work

While targeted therapies improve treatment, they do not work for everyone. Patients must undergo molecular profiling—such as Next-Generation Sequencing (NGS)—to determine if their tumor harbors the specific ALK mutation. These medications are contraindicated for patients whose tumors lack the targeted genetic alteration, as they would provide no clinical benefit.

Individuals experiencing persistent, unexplained bone pain, chronic coughing, or shortness of breath—regardless of smoking status—should consult a primary care provider. If imaging reveals suspicious lesions, referral to an orthopedic oncologist or a medical oncologist is the standard of care for definitive tissue diagnosis and staging.

Bickerstaff Shows Positive Response to Investigational Therapy

Bickerstaff’s response to the investigational therapy has been positive, with recent scans indicating regression at all primary cancer sites. Dr. Haggstrom notes that the patient has experienced minimal side effects, a common objective in the development of third-generation targeted inhibitors.

Bickerstaff’s care team says lung cancer can develop in non-smokers and calls for more research and awareness during Lung Cancer Awareness Month this November. Bickerstaff, currently in recovery, is now looking toward restoring his 1966 Mustang Fastback and planning family travel, marking a return to daily life facilitated by his response to the trial medication.

More on Lung Cancer: Lung-RADS v2022 Speeds Diagnosis of Cystic Airspace Lung Cancer